Nucleic Acids Research, 2003, Vol. 31, No. 12 3123-3133
© 2003 Oxford University Press
Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene
Laboratory of Biochemistry and Molecular Biology, The Wheeler Institute for Biomedical Research, Johns Hopkins University Bayview Campus, Baltimore, MD 21224, USA
*To whom correspondence should be addressed. Tel/Fax: +1 410 558 7050; Email: racurrie{at}sprintmail.com
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
The high-mobility-group A2 protein (HMGA2) plays important functional roles in transcriptional regulation, DNA replication and chromatin structure. In this study, the effect of histone deacetylase inhibition on the transcriptional activity of the Hmga2 gene was investigated in vivo both at the endogenous gene level and in a variety of cell lines using transiently transfected promoter constructs. Trichostatin A (TSA) repressed both transfected murine and human Hmga2 promoter constructs 3–8-fold in NIH3T3, F9 and HeLa cells. Steady-state Hmga2 mRNA levels in NIH3T3 cells decreased 4–5-fold following TSA treatment, while pre- treatment of NIH3T3 cells with the transcriptional inhibitor, actinomycin D, completely blocked TSA mediated repression of the Hmga2 gene. Cross-linked chromatin immunoprecipitation (X-ChIP) analysis revealed a 5–6-fold decrease in endogenous Hmga2 promoter bound Sp1 and Sp3 proteins following TSA treatment in parallel with observed loss of acetylated histone H3 and H4. In addition, the poly-pyrimidine-tract-binding protein (PTB) was observed to bind to the Hmga2 promoter in both TSA treated and untreated NIH3T3 cells. Together, these results suggest TSA treatment leads to a decrease in Hmga2 gene transcription, and a significant decrease in promoter bound Sp1, Sp3 and acetylated histones H3 and H4.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. S.Q. Kortenhorst, S. Isharwal, P. J. van Diest, W. H. Chowdhury, C. Marlow, M. A. Carducci, R. Rodriguez, and R. W. Veltri Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo Mol. Cancer Ther., April 1, 2009; 8(4): 802 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vincent, M.-P. Ducourouble, and I. Van Seuningen Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases FASEB J, August 1, 2008; 22(8): 3035 - 3045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Abramovitz, T. Shapira, I. Ben-Dror, V. Dror, L. Granot, T. Rousso, E. Landoy, L. Blau, G. Thiel, and L. Vardimon Dual Role of NRSF/REST in Activation and Repression of the Glucocorticoid Response J. Biol. Chem., January 4, 2008; 283(1): 110 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shlapobersky, R. Sanders, C. Clark, and D. H. Spector Repression of HMGA2 Gene Expression by Human Cytomegalovirus Involves the IE2 86-Kilodalton Protein and Is Necessary for Efficient Viral Replication and Inhibition of Cyclin A Transcription. J. Virol., October 1, 2006; 80(20): 9951 - 9961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Matheu, P. Klatt, and M. Serrano Regulation of the INK4a/ARF Locus by Histone Deacetylase Inhibitors J. Biol. Chem., December 23, 2005; 280(51): 42433 - 42441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Duan, C. A. Heckman, and L. M. Boxer Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas Mol. Cell. Biol., March 1, 2005; 25(5): 1608 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Dehm, T. L. Hilton, E. H. Wang, and K. Bonham SRC Proximal and Core Promoter Elements Dictate TAF1 Dependence and Transcriptional Repression by Histone Deacetylase Inhibitors Mol. Cell. Biol., March 15, 2004; 24(6): 2296 - 2307. [Abstract] [Full Text] [PDF]
|
|